DNA methylation markers in colorectal cancer.

Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15

Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06

Environmental chemical exposures and human epigenetics. Int J Epidemiol (2011) 1.97

Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev (2012) 1.57

Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol (2011) 1.50

Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med (2012) 1.47

Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol (2014) 1.35

A genome-wide DNA methylation study in colorectal carcinoma. BMC Med Genomics (2011) 1.27

Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int (2012) 1.24

Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer (2011) 1.22

Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence. BMC Cancer (2013) 1.18

MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res (2014) 1.17

Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today (2010) 1.15

Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res (2010) 1.12

Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One (2013) 1.09

Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog Res Int (2012) 1.07

SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene (2011) 1.06

DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett (2013) 1.03

Interpretation of genome-wide infinium methylation data from ligated DNA in formalin-fixed, paraffin-embedded paired tumor and normal tissue. BMC Res Notes (2012) 1.02

Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol (2014) 1.02

Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia. Inflamm Bowel Dis (2011) 1.01

Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics (2013) 1.00

DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer (2011) 0.99

MeInfoText 2.0: gene methylation and cancer relation extraction from biomedical literature. BMC Bioinformatics (2011) 0.97

NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genet (2013) 0.96

Cancer epigenetics: above and beyond. Toxicol Mech Methods (2011) 0.95

Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol (2011) 0.95

Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. Neoplasia (2012) 0.95

Epigenetic changes in colorectal cancer. Chin J Cancer (2011) 0.94

A minimal set of tissue-specific hypomethylated CpGs constitute epigenetic signatures of developmental programming. PLoS One (2013) 0.93

Folate depletion during pregnancy and lactation reduces genomic DNA methylation in murine adult offspring. Genes Nutr (2010) 0.92

Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer (2014) 0.92

Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. J Exp Clin Cancer Res (2014) 0.92

Molecular markers for colorectal cancer screening. Gut (2015) 0.92

DNA methylation and histone modifications of Wnt genes by genistein during colon cancer development. Carcinogenesis (2013) 0.91

Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91

Accumulation of aberrant DNA methylation during colorectal cancer development. World J Gastroenterol (2014) 0.90

Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer (2011) 0.90

Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion. Discov Med (2013) 0.89

Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation. Nat Commun (2012) 0.89

MethyQA: a pipeline for bisulfite-treated methylation sequencing quality assessment. BMC Bioinformatics (2013) 0.89

Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol (2013) 0.89

DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol (2012) 0.88

Loss of HLTF function promotes intestinal carcinogenesis. Mol Cancer (2012) 0.88

DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett (2014) 0.88

Screening of potential diagnostic markers and therapeutic targets against colorectal cancer. Onco Targets Ther (2015) 0.88

The interaction between epigenetics, nutrition and the development of cancer. Nutrients (2015) 0.87

A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clin Transl Gastroenterol (2012) 0.85

Identifying hypermethylated CpG islands using a quantile regression model. BMC Bioinformatics (2011) 0.84

A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment. J Transl Med (2011) 0.84

Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn (2012) 0.84

The homeobox only protein homeobox (HOPX) and colorectal cancer. Int J Mol Sci (2013) 0.84

Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma. Exp Biol Med (Maywood) (2015) 0.84

DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer (2015) 0.83

Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol (2015) 0.83

Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Colorectal Dis (2012) 0.83

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. PLoS One (2015) 0.83

Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer (2013) 0.83

DNA Methylation and Colorectal Cancer. Curr Colorectal Cancer Rep (2014) 0.82

Decreased expression of 17β-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon. BMC Cancer (2011) 0.82

Fecal molecular markers for colorectal cancer screening. Gastroenterol Res Pract (2011) 0.82

Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis. World J Gastroenterol (2014) 0.82

Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. J Cancer (2013) 0.82

A cross-sectional study of global DNA methylation and risk of colorectal adenoma. BMC Cancer (2014) 0.80

Meta-analysis of the association between APC promoter methylation and colorectal cancer. Onco Targets Ther (2015) 0.80

Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer. Epigenetics (2016) 0.79

Enhancement of Pathologist's Routine Practice: Reuse of DNA Extracted from Immunostained Formalin-fixed Paraffin-embedded (FFPE) Slides in Downstream Molecular Analysis of Cancer. Cancer Genomics Proteomics (2016) 0.79

Identifying molecular subtypes in human colon cancer using gene expression and DNA methylation microarray data. Int J Oncol (2015) 0.79

DNA methylation combinations in adjacent normal colon tissue predict cancer recurrence: evidence from a clinical cohort study. PLoS One (2015) 0.78

hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis (2012) 0.78

Terahertz molecular resonance of cancer DNA. Sci Rep (2016) 0.78

Classification of Colon Cancer Patients Based on the Methylation Patterns of Promoters. Genomics Inform (2016) 0.78

The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci (2016) 0.77

Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol Lett (2016) 0.77

Multi-target siRNA based on DNMT3A/B homologous conserved region influences cell cycle and apoptosis of human prostate cancer cell line TSU-PR1. Genet Mol Biol (2012) 0.77

Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn (2015) 0.77

DDMGD: the database of text-mined associations between genes methylated in diseases from different species. Nucleic Acids Res (2014) 0.77

Quantitative analysis of cancer-associated gene methylation connected to risk factors in Korean colorectal cancer patients. J Prev Med Public Health (2012) 0.76

Field Cancerization in Sporadic Colon Cancer. Gut Liver (2016) 0.76

Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells. PLoS One (2015) 0.76

Epigenetic Methylation of Parathyroid CaR and VDR Promoters in Experimental Secondary Hyperparathyroidism. Int J Nephrol (2012) 0.76

Promoter hypermethylation and downregulation of the FAS gene may be involved in colorectal carcinogenesis. Oncol Lett (2016) 0.75

CGPredictor: a systematic integrated analytic tool for mining and examining genome-scale cancer independent prognostic epigenetic marker panels. BMC Syst Biol (2013) 0.75

Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer. Adv Biomed Res (2015) 0.75

Epigenetic silencing of protocadherin 10 in colorectal cancer. Oncol Lett (2017) 0.75

Hyper-Methylated Loci Persisting from Sessile Serrated Polyps to Serrated Cancers. Int J Mol Sci (2017) 0.75

Predicting the progress of colon cancer by DNA methylation markers of the p16 gene in feces - Evidence from an animal model. Genet Mol Biol (2013) 0.75

Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells. Genet Res Int (2016) 0.75

Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. Cancers (Basel) (2017) 0.75

Early detection: the impact of genomics. Virchows Arch (2017) 0.75

DNA hypomethylation of CBS promoter induced by folate deficiency is a potential noninvasive circulating biomarker for colorectal adenocarcinomas. Oncotarget (2017) 0.75

Identification of novel methylated targets in colorectal cancer by microarray analysis and construction of co-expression network. Oncol Lett (2017) 0.75

Sarcopenia is associated with an increased risk of advanced colorectal neoplasia. Int J Colorectal Dis (2016) 0.75

The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancers. J Cancer (2017) 0.75

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09

BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20

TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74

Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66

MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56

The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54

p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54

DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46

Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31

Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20

Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19

A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05

Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97

Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88

Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80

Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76

Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74

Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72

Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70

Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70

Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69

Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68

Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66

Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66

Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65

Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63

Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62

Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59

Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res (2003) 1.59

Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics (2010) 1.57

Mitochondrial subversion in cancer. Cancer Prev Res (Phila) (2011) 1.54

Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54

Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53

Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53

Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51

DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell (2002) 1.51

Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47

OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47

Mouse mammary tumor-like env gene as a molecular marker for breast cancer? Int J Cancer (2002) 1.47

Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res (2002) 1.46

Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg (2002) 1.46

Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45

Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer (2005) 1.45

DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44

Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43

Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res (2008) 1.41

An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. J Mol Diagn (2006) 1.40

An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res (2011) 1.37

N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res (2006) 1.36

Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res (2004) 1.35

PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res (2005) 1.34

Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res (2004) 1.32

RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle (2004) 1.31

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30

Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27

Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer (2004) 1.27

Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci (2003) 1.26

Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res (2010) 1.26

KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer (2010) 1.26

Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res (2005) 1.26

Role of human aquaporin 5 in colorectal carcinogenesis. Am J Pathol (2008) 1.25

Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol (2002) 1.24

Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest (2005) 1.24

Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23

P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem (2003) 1.23

Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett (2008) 1.23

Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol (2011) 1.21

Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res (2003) 1.20

Mitochondrial DNA content increase in response to cigarette smoking. Cancer Epidemiol Biomarkers Prev (2006) 1.20

Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res (2004) 1.19

Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res (2010) 1.18

DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle (2005) 1.18

MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.18

Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. PLoS One (2008) 1.17

Aquaporin expression in human lymphocytes and dendritic cells. Am J Hematol (2004) 1.17

Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer (2005) 1.17

High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res (2003) 1.16